QTTB Q32 Bio Inc.

QTTB financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1661998 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Nov 4, 2026 Data checked: Nov 10, 2026
Showing 3 of 9 annual and 0 of 39 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$10.40M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
781-999-0232
EIN
473468154
Headquarters
WALTHAM, MA, 02451
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: Q32 Bio Inc. (2024–2026) · Homology Medicines, Inc. (2016–2024)

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
-
Net Income
$32.25M
Total Assets
$297.20M
Total Equity
$287.67M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
11.2%
Return on Assets
10.9%
Current Ratio
56.34x

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

In fiscal 2025, Q32 Bio Inc. recorded $53.74M of revenue, net income of $29.82M, and an operating cash outflow of $33.54M. The $53.74M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. The company reported diluted EPS of $2.42, adding a shareholder-level measure to the absolute income figures considered below. Diluted shares averaged 12.31M; this is the reported share base over which the company’s diluted per-share earnings were spread. Compared with 9.66M diluted shares in fiscal 2024, the current 12.31M base was 27.5% higher. Total assets stood at $61.78M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. Asset turnover was 0.87x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

The reported operating result was $16.90M, capturing profitability after direct costs and the operating expenses reflected in the statements. Relative to revenue, operating income represented 31.5%, showing how efficiently sales converted into operating profit. After all reported below-operating-line items, the company recorded net income of $29.82M for the fiscal year. Measured against reported revenue, net income produced a 55.5% margin after operating costs and the remaining recognized items. Reported EBITDA totaled $17.29M, adding a pre-interest, tax, depreciation, and amortization perspective to the profitability profile. The company recognized $0.00 of income tax for the period, completing the transition from pretax income to net income. Return on period-end equity was 71.0%, relating annual net income to the equity capital on the balance sheet. Return on period-end assets was 48.3%, connecting net income with the company’s total asset base. Net income of $29.82M replaced the $47.73M loss reported in fiscal 2024.

Liquidity and Capital Structure

The company held $61.78M of assets against $19.76M of liabilities and $42.01M of equity, revealing how the asset base was financed. At period end, current assets of $55.05M compared with current liabilities of $11.35M, defining the company’s short-term resource position. At 4.85x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Reported cash and equivalents were $48.30M, separating immediately recognizable cash resources from the rest of the current-asset base. The cash balance equaled 425.7% of current liabilities, showing how much near-term coverage came from cash alone. The equity-to-assets relationship was 68.0%, placing book capital against the total resource base. Liabilities represented 32.0% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 78.2% of total assets, showing the liquid cash component within the company’s broader resource base. The asset base changed 33.1% from $92.33M in fiscal 2024, leaving current total assets lower year over year. Book equity was 640.3% higher than fiscal 2024 equity of $5.67M, showing how shareholder capital changed year over year. The reported cash balance changed 38.1% from $77.97M in fiscal 2024, ending lower year over year.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $33.54M, rather than cash generation from operations. Operating cash flow and capital spending combined to leave a $33.54M cash deficit after capital spending. Relative to revenue, the post-investment cash deficit represented 62.4%. The cash deficit after capital spending represented 54.3% of the period-end asset base. Cash absorbed by operations decreased from $67.72M in fiscal 2024 to $33.54M.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Q32 Bio Inc.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $53.74M $0 $-6.65M
OPERATING EXPENSES
R&D Expense $19.16M $48.14M $31.73M
SG&A Expense $17.68M $17.96M $9.88M
Operating Income $16.90M $-66.10M $-48.26M
NON-OPERATING INCOME / EXPENSE
Interest Expense - - $1.50M
Other Income/Expense $1.18M $4.13M $1.02M
Pretax Income - - $-87.08M
Income Tax $0 $21.00K $318.00K
Net Income $29.82M $-47.73M $-53.74M
PER SHARE & SUPPLEMENTAL
Diluted EPS $2.42 $-6.58 $-153.96
Diluted Shares 12.31M 9.66M 349.06K
EBITDA $17.29M $-65.62M $-47.76M
Depreciation & Amortization $391.00K $487.00K $499.00K
Balance Sheet
ASSETS
Cash & Equivalents $48.30M $77.97M $25.62M
Short-term Investments - $0 $0
Other Current Assets $20.00K $396.00K $83.00K
Current Assets $55.05M $81.88M $28.72M
PP&E (Net) $979.00K $1.37M $1.78M
Other Noncurrent Assets $0 $116.00K $4.61M
Noncurrent Assets $6.73M $10.46M $18.34M
Total Assets $61.78M $92.33M $47.06M
LIABILITIES
Accounts Payable $879.00K $2.99M $3.47M
Other Current Liabilities - - $325.00K
Current Liabilities $11.35M $16.47M $14.11M
Other Noncurrent Liabilities $0 $55.00M $55.00M
Noncurrent Liabilities $8.42M $70.19M $104.42M
Total Liabilities $19.76M $86.66M $118.53M
EQUITY
Common Stock $2.00K $2.00K $1.00K
Additional Paid-in Capital $247.01M $240.49M $4.16M
Retained Earnings $-204.99M $-234.81M $-187.08M
Accumulated OCI - $0 $0
Total Equity $42.01M $5.68M $-182.92M
Temporary Equity - - $111.45M
Total Liabilities & Equity $61.78M $92.33M $47.06M
SUPPLEMENTAL
Shares Outstanding 12.86M 12.20M 359.57K
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-33.54M $-67.72M $-18.68M
Capital Expenditures $0 $75.00K $5.00K
Cash from Investing $7.00M $19.93M $-5.00K
Cash from Financing $-3.13M $95.14M $406.00K
Free Cash Flow $-33.54M $-67.79M $-18.68M
Beginning Cash (CFS) $78.61M $31.26M $49.54M
Net Change in Cash $-29.67M $47.35M $-18.28M
Effect of FX on Cash - - -
Calculated Ending Cash $48.94M $78.61M $31.26M
Cash per BS $48.30M $77.97M $25.62M
Cash scope difference (CFS − BS) $647.00K $647.00K $5.65M
Cash per CFS $48.94M $78.61M $31.26M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

Is Q32 Bio Inc. profitable?

Yes. Q32 Bio Inc. reported $32.25M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.